The estimated Net Worth of Karen Prange is at least $1.36 million dollars as of 19 July 2023. Ms. Prange owns over 129,466 units of Nevro Corp stock worth over $41,443 and over the last 12 years she sold NVRO stock worth over $1,019,405. In addition, she makes $302,071 as Independent Director at Nevro Corp.
Karen has made over 19 trades of the Nevro Corp stock since 2013, according to the Form 4 filled with the SEC. Most recently she sold 129,466 units of NVRO stock worth $9,063 on 19 July 2023.
The largest trade she's ever made was selling 129,466 units of Nevro Corp stock on 19 July 2023 worth over $9,063. On average, Karen trades about 8,187 units every 87 days since 2013. As of 19 July 2023 she still owns at least 8,799 units of Nevro Corp stock.
You can see the complete history of Ms. Prange stock trades at the bottom of the page.
Karen N. Prange serves as Independent Director of the Company. From May 2016 to April 2018, Ms. Prange was Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein and a member of its Executive Committee. Prior to that, Ms. Prange was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health business from June 2012 to May 2016. Prior to working at Boston Scientific, Ms. Prange also held several leadership positions in increasing levels of responsibility at Johnson and Johnson Company, most recently as General Manager of the Micrus Endovascular and Codman Neurovascular business. Ms. Prange currently serves on the boards of Atricure and Cantel Medical and is a strategic advisor for Nuvo Group. Ms. Prange earned her B.S. in Business Administration with honors from the University of Florida and has completed executive education coursework at UCLA Anderson School of Business and Smith College.
As the Independent Director of Nevro Corp, the total compensation of Karen Prange at Nevro Corp is $302,071. There are 12 executives at Nevro Corp getting paid more, with D.Keith Grossman having the highest compensation of $13,877,700.
Karen Prange is 56, she's been the Independent Director of Nevro Corp since 2019. There are 17 older and 7 younger executives at Nevro Corp. The oldest executive at Nevro Corp is Frank Fischer, 78, who is the Independent Director.
Karen's mailing address filed with the SEC is 7555, Innovation Way, Innovation Business Center, Mason, Warren County, Ohio, 45040, United States.
Over the last 10 years, insiders at Nevro Corp have traded over $298,472,982 worth of Nevro Corp stock and bought 312,708 units worth $8,709,518 . The most active insiders traders include Ali Behbahani, Holdings A/S Novo et & Johnson Johnson & Johnson.... On average, Nevro Corp executives and independent directors trade stock every 18 days with the average trade being worth of $161,002. The most recent stock trade was executed by Shawn Mc Cormick on 7 June 2023, trading 7,500 units of NVRO stock currently worth $171,600.
headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.
Nevro Corp executives and other stock owners filed with the SEC include: